Stephen Biggar - Argus Research
02/22/2017 10:16 am EST
Vickers Stock Research, Argus’ sister company, calculates proprietary Sell/Buy Ratios using data from recent Form-4 filings (through which insiders register purchases and sales of their stock with the SEC).
Insiders at Athersys (ATHX), have recently taken advantage of the company offering a total of 22,772,300 shares at an offering price of $1.01. On the first of February, insiders purchased a total of 282,500 shares.
The ATHX share price fell sharply following the release of third-quarter results on November 9, when the company provided updates on various agreements, clinical trials and discussions with regulators.
In the fourth quarter of 2016, Athersys received a $0.6 million development milestone from Bristol-Myers Squibb (BMY) related to a legacy drug target program.
Also, a large group of insiders at Novavax (NVAX) have increased their holdings. Since the collapse of the share price in September, insiders have acquired a total of 287,994 shares. Purchasers include the SVP & CFO; SVP & General Counsel; SVP of Commercial Operations; President of R&D; and several Directors.
The company describes itself as a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. It says that it is working on a groundbreaking innovation that improves global health through safe and effective vaccines.